Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. Appropriate drug selection remains crucial in this evolving landscape to derive maximum benefit for the patients. We summarize clinical trials leading to recent drug approvals and discuss optimal treatment selection. We also review recent advances in genomics including its evolving role in prognosis, in elucidating mechanisms of treatment resistance, and in guiding treatment decisions.
Trends in cancer. 2020 Jun 10 [Epub]
Umang Swami, Taylor R McFarland, Roberto Nussenzveig, Neeraj Agarwal
Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: .